Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

BACKGROUND: Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatmen...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Infect Dis
Päätekijät: File, Thomas M, Goldberg, Lisa, Das, Anita, Sweeney, Carolyn, Saviski, John, Gelone, Steven P, Seltzer, Elyse, Paukner, Susanne, Wicha, Wolfgang W, Talbot, George H, Gasink, Leanne B
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Articles and Commentaries
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853694/
https://ncbi.nlm.nih.gov/pubmed/30722059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciz090
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia